DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures
The current program has the potential to advance its MCM candidate towards a marketing authorization application at the end of the four-year funding period.
- The current program has the potential to advance its MCM candidate towards a marketing authorization application at the end of the four-year funding period.
- Beyond its potential as a medical countermeasure, the MCM portfolio has several promising clinical applications in mitigating radiation and chemotherapy-induced toxicity in nuclear medicine and (radiation) oncology.
- About Eckert & Ziegler: Eckert & Ziegler Strahlen- und Medizintechnik AG with its 900 employees, is a leading global specialist for isotope-related applications in nuclear medicine, industry, and radiation therapy.
- The primary manifestation of ARS is the depletion of hematopoietic stem and progenitor cells, constituting one of the major causes of mortality.